Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Esophagus
Published in: Esophagus 3/2023

Open Access 30-03-2023 | Esophageal Cancer | Special Article

Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2

Authors: Yuko Kitagawa, Ryu Ishihara, Hitoshi Ishikawa, Yoshinori Ito, Takashi Oyama, Tsuneo Oyama, Ken Kato, Hiroyuki Kato, Hirofumi Kawakubo, Hiroshi Kawachi, Shiko Kuribayashi, Koji Kono, Takashi Kojima, Hiroya Takeuchi, Takahiro Tsushima, Yasushi Toh, Kenji Nemoto, Eisuke Booka, Tomoki Makino, Satoru Matsuda, Hisahiro Matsubara, Masayuki Mano, Keiko Minashi, Tatsuya Miyazaki, Manabu Muto, Taiki Yamaji, Tomoki Yamatsuji, Masahiro Yoshida

Published in: Esophagus | Issue 3/2023

Login to get access

Excerpt

In patients in whom complete response to definitive chemoradiotherapy for esophageal cancer has been achieved, computed tomography (CT) or endoscopic surveillance should be conducted to detect recurrence. Since intraesophageal recurrence, if detected early, is expected to be cured by salvage therapy, endoscopic surveillance is important from the standpoint of both the quality of life (QOL) and the prognosis. …
Literature
1.
Mayanagi S, Onitsuka T, Nakagawa M, et al. The use of short segment free jejunal transfer as salvage surgery for cervical esophageal and hypopharyngeal cancer. World J Surg. 2014;38(1):144–9.PubMedCrossRef
2.
Ullah R, Bailie N, Kinsella J, et al. Pharyngo-laryngo-oesophagectomy and gastric pull-up for post-cricoid and cervical oesophageal squamous cell carcinoma. J Laryngol Otol. 2002;116(10):826–30.PubMedCrossRef
3.
Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380(2):152–62.PubMedCrossRef
4.
Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379(9829):1887–92.PubMedCrossRef
5.
Straatman J, van der Wielen N, Cuesta MA, et al. Minimally invasive versus open esophageal resection: three-year follow-up of the previously reported randomized controlled trial: the TIME trial. Ann Surg. 2017;266(2):232–6.PubMedCrossRef
6.
Mederos MA, de Virgilio MJ, Shenoy R, et al. Comparison of clinical outcomes of robot-assisted, video-assisted, and open esophagectomy for esophageal cancer: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(11): e2129228.PubMedPubMedCentralCrossRef
7.
Coelho FDS, Barros DE, Santos FA, et al. Minimally invasive esophagectomy versus open esophagectomy: a systematic review and meta-analysis. Eur J Surg Oncol. 2021;47(11):2742–8.PubMedCrossRef
8.
Fearon KC, Ljungqvist O, Von Meyenfeldt M, et al. Enhanced recovery after surgery: a consensus review of clinical care for patients undergoing colonic resection. Clin Nutr. 2005;24(3):466–77.PubMedCrossRef
9.
Markar SR, Karthikesalingam A, Low DE. Enhanced recovery pathways lead to an improvement in postoperative outcomes following esophagectomy: systematic review and pooled analysis. Dis Esophagus. 2015;28(5):468–75.PubMedCrossRef
10.
Low DE, Allum W, De Manzoni G, et al. Guidelines for perioperative care in esophagectomy: enhanced recovery after surgery (ERAS®) society recommendations. World J Surg. 2019;43(2):299–330.PubMedCrossRef
11.
Triantafyllou T, Olson MT, Theodorou D, et al. Enhanced recovery pathways vs standard care pathways in esophageal cancer surgery: systematic review and meta-analysis. Esophagus. 2020;17(2):100–12.PubMedCrossRef
12.
Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16(1):25–43.PubMedCrossRef
13.
Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 1. Esophagus. 2019;16(1):1–24.PubMedCrossRef
14.
Yamana I, Takeno S, Hashimoto T, et al. Randomized controlled study to evaluate the efficacy of a preoperative respiratory rehabilitation program to prevent postoperative pulmonary complications after esophagectomy. Dig Surg. 2015;32(5):331–7.PubMedCrossRef
15.
Weimann A, Braga M, Carli F, et al. ESPEN guideline: clinical nutrition in surgery. Clin Nutr. 2017;36(3):623–50.PubMedCrossRef
16.
17.
Ashok A, Niyogi D, Ranganathan P, et al. The enhanced recovery after surgery (ERAS) protocol to promote recovery following esophageal cancer resection. Surg Today. 2020;50(4):323–34.PubMedPubMedCentralCrossRef
18.
Soutome S, Hasegawa T, Yamguchi T, et al. Prevention of postoperative pneumonia by perioperative oral care in patients with esophageal cancer undergoing surgery: a multicenter retrospective study of 775 patients. Support Care Cancer. 2020;28(9):4155–62.PubMedCrossRef
19.
Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol. 2003;21(24):4592–6.PubMedCrossRef
20.
Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74.PubMedCrossRef
21.
Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92.PubMedCrossRef
22.
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.PubMedCrossRef
23.
Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203.PubMedCrossRef
24.
Kato K, Ito Y, Daiko H, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol. 2022;40(4_suppl):238.CrossRef
25.
Kato K, Ito Y, Nozaki I, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with Stage I esophageal squamous cell carcinoma. Gastroenterology. 2021;161(6):1878-86.e2.PubMedCrossRef
26.
Motoori M, Yano M, Ishihara R, et al. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer. Ann Surg Oncol. 2012;19(7):2135–41.PubMedCrossRef
27.
Igaki H, Kato H, Tachimori Y, et al. Clinicopathologic characteristics and survival of patients with clinical Stage I squamous cell carcinomas of the thoracic esophagus treated with three-field lymph node dissection. Eur J Cardiothorac Surg. 2001;20(6):1089–94.PubMedCrossRef
28.
Kawaguchi G, Sasamoto R, Abe E, et al. The effectiveness of endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer. Radiat Oncol. 2015;10:31.PubMedPubMedCentralCrossRef
29.
Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for Stage I esophageal squamous cell carcinoma. Gastroenterology. 2019;157(2):382-90.e3.PubMedCrossRef
30.
Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–74.PubMedCrossRef
31.
Takeuchi H, Ito Y, Machida R, et al. A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical Stage II/III esophageal squamous cell carcinoma (JCOG0909 study). Int J Radiat Oncol Biol Phys. 2022;114(3):454–62.PubMedCrossRef
32.
Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17(9):2915–21.PubMedCrossRef
33.
Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004;34(10):615–9.PubMedCrossRef
34.
Nishimura Y, Hiraoka M, Koike R, et al. Long-term follow-up of a randomized Phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol. 2012;42(9):807–12.PubMedCrossRef
35.
Shinoda M, Ando N, Kato K, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106(4):407–12.PubMedPubMedCentralCrossRef
36.
Higuchi K, Koizumi W, Tanabe S, et al. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501). Radiother Oncol. 2008;87(3):398–404.PubMedCrossRef
37.
Yokota T, Kato K, Hamamoto Y, et al. A 3-year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Ann Surg Oncol. 2020;27(2):460–7.PubMedCrossRef
38.
Terada M, Hara H, Daiko H, et al. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Jpn J Clin Oncol. 2019;49(11):1055–60.PubMedCrossRef
39.
Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623–7.PubMedCrossRef
40.
Wong RK, Malthaner RA, Zuraw L, et al. Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline. Int J Radiat Oncol Biol Phys. 2003;55(4):930–42.PubMedCrossRef
41.
Hulshof M, Geijsen ED, Rozema T, et al. Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study). J Clin Oncol. 2021;39(25):2816–24.PubMedCrossRef
42.
Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21(14):2697–702.PubMedCrossRef
43.
Wang X, Palaskas NL, Yusuf SW, et al. Incidence and onset of severe cardiac events after radiotherapy for esophageal cancer. J Thorac Oncol. 2020;15(10):1682–90.PubMedPubMedCentralCrossRef
44.
Asakura H, Hashimoto T, Zenda S, et al. Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer. Radiother Oncol. 2010;95(2):240–4.PubMedCrossRef
45.
Xu D, Li G, Li H, et al. Comparison of IMRT versus 3D-CRT in the treatment of esophagus cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(31): e7685.PubMedCrossRef
46.
Lin SH, Hobbs BP, Verma V, et al. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. J Clin Oncol. 2020;38(14):1569–79.PubMedPubMedCentralCrossRef
47.
Akutsu Y, Yasuda S, Nagata M, et al. A phase I/II clinical trial of preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus. J Surg Oncol. 2012;105(8):750–5.PubMedCrossRef
48.
Tachimori Y, Kanamori N, Uemura N, et al. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2009;137(1):49–54.PubMedCrossRef
49.
Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123(1):175–83.PubMedCrossRef
50.
Meunier B, Raoul J, Le Prisé E, et al. Salvage esophagectomy after unsuccessful curative chemoradiotherapy for squamous cell cancer of the esophagus. Dig Surg. 1998;15(3):224–6.PubMedCrossRef
51.
Nakamura T, Hayashi K, Ota M, et al. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg. 2004;188(3):261–6.PubMedCrossRef
52.
Takeuchi H, Saikawa Y, Oyama T, et al. Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy. World J Surg. 2010;34(2):277–84.PubMedCrossRef
53.
Yano T, Muto M, Hattori S, et al. Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy. 2008;40(9):717–21.PubMedCrossRef
54.
Makazu M, Kato K, Takisawa H, et al. Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer. Dis Esophagus. 2014;27(1):42–9.PubMedCrossRef
55.
Hatogai K, Yano T, Kojima T, et al. Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer. Radiat Oncol. 2016;11:31.PubMedPubMedCentralCrossRef
56.
Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593–8.PubMedCrossRef
57.
58.
Toh Y, Numasaki H, Tachimori Y, et al. Current status of radiotherapy for patients with thoracic esophageal cancer in Japan, based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society. Esophagus. 2020;17(1):25–32.PubMedCrossRef
59.
Kawashima M, Kagami Y, Toita T, et al. Prospective trial of radiotherapy for patients 80 years of age or older with squamous cell carcinoma of the thoracic esophagus. Int J Radiat Oncol Biol Phys. 2006;64(4):1112–21.PubMedCrossRef
60.
Nishimura Y, Ono K, Tsutsui K, et al. Esophageal cancer treated with radiotherapy: impact of total treatment time and fractionation. Int J Radiat Oncol Biol Phys. 1994;30(5):1099–105.PubMedCrossRef
61.
Miyata H, Yamasaki M, Kurokawa Y, et al. Survival factors in patients with recurrence after curative resection of esophageal squamous cell carcinomas. Ann Surg Oncol. 2011;18(12):3353–61.PubMedCrossRef
62.
Toh Y, Oki E, Minami K, et al. Follow-up and recurrence after a curative esophagectomy for patients with esophageal cancer: the first indicators for recurrence and their prognostic values. Esophagus. 2010;7(1):37–43.CrossRef
63.
Abate E, DeMeester SR, Zehetner J, et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg. 2010;210(4):428–35.PubMedCrossRef
64.
Depypere L, Lerut T, Moons J, et al. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road. Dis Esophagus. 2017;30(1):1–8.PubMed
65.
Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32(5):385–91.PubMedCrossRef
66.
Sugiyama M, Morita M, Yoshida R, et al. Patterns and time of recurrence after complete resection of esophageal cancer. Surg Today. 2012;42(8):752–8.PubMedCrossRef
67.
Toh Y, Kitagawa Y, Kuwano H, et al. A nation-wide survey of follow-up strategies for esophageal cancer patients after a curative esophagectomy or a complete response by definitive chemoradiotherapy in Japan. Esophagus. 2016;13(2):173–81.CrossRef
68.
Nakanoko T, Morita M, Nakashima Y, et al. Nationwide survey of the follow-up practices for patients with esophageal carcinoma after radical treatment: historical changes and future perspectives in Japan. Esophagus. 2022;19(1):69–76.PubMedCrossRef
69.
Toh Y, Morita M, Yamamoto M, et al. Health-related quality of life after esophagectomy in patients with esophageal cancer. Esophagus. 2022;19(1):47–56.PubMedCrossRef
70.
Chuang SC, Hashibe M, Scelo G, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1543–9.PubMedCrossRef
71.
Katada C, Tanabe S, Koizumi W, et al. Narrow band imaging for detecting superficial squamous cell carcinoma of the head and neck in patients with esophageal squamous cell carcinoma. Endoscopy. 2010;42(3):185–90.PubMedCrossRef
72.
van de Ven S, Bugter O, Hardillo JA, et al. Screening for head and neck second primary tumors in patients with esophageal squamous cell cancer: a systematic review and meta-analysis. United Eur Gastroenterol J. 2019;7(10):1304–11.CrossRef
73.
Hamai Y, Hihara J, Emi M, et al. Treatment outcomes and prognostic factors after recurrence of esophageal squamous cell carcinoma. World J Surg. 2018;42(7):2190–8.PubMedCrossRef
74.
Kudou K, Saeki H, Nakashima Y, et al. Clinical outcomes of surgical resection for recurrent lesion after curative esophagectomy for esophageal squamous cell carcinoma: a nationwide, large-scale retrospective study. Esophagus. 2022;19(1):57–68.PubMedCrossRef
75.
Ma X, Zhao K, Guo W, et al. Salvage lymphadenectomy versus salvage radiotherapy/chemoradiotherapy for recurrence in cervical lymph node after curative resection of esophageal squamous cell carcinoma. Ann Surg Oncol. 2015;22(2):624–9.PubMedCrossRef
76.
Jingu K, Matsushita H, Takeda K, et al. Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. BMC Cancer. 2012;12:542.PubMedPubMedCentralCrossRef
77.
Ohkura Y, Shindoh J, Ueno M, et al. Clinicopathologic characteristics of oligometastases from esophageal cancer and long-term outcomes of resection. Ann Surg Oncol. 2020;27(3):651–9.PubMedCrossRef
78.
Watanabe M, Mine S, Yamada K, et al. Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus. Gen Thorac Cardiovasc Surg. 2014;62(11):685–92.PubMedCrossRef
79.
Chen J, Yin W, Yao H, et al. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma. Radiat Oncol. 2019;14(1):169.PubMedPubMedCentralCrossRef
80.
81.
Hellstadius Y, Lagergren J, Zylstra J, et al. Prevalence and predictors of anxiety and depression among esophageal cancer patients prior to surgery. Dis Esophagus. 2016;29(8):1128–34.PubMedCrossRef
82.
Schweigert M, Dubecz A, Stein HJ. Oesophageal cancer—an overview. Nat Rev Gastroenterol Hepatol. 2013;10(4):230–44.PubMedCrossRef
83.
Ishii K, Tsubosa Y, Niihara M, et al. Palliative radiotherapy to maintain outpatient status in elderly patients with esophageal carcinoma. Ann Palliat Med. 2021;10(2):1779–83.PubMedCrossRef
84.
85.
Watanabe M, Sato M, Fukuchi M, et al. Treatment of aortoesophageal fistula developed after thoracic endovascular aortic repair: a questionnaire survey study. Esophagus. 2020;17(1):81–6.PubMedCrossRef
86.
Song JH, Ko J, Min YW, et al. Comparison between percutaneous gastrostomy and self-expandable metal stent insertion for the treatment of malignant esophageal obstruction, after propensity score matching. Nutrients. 2020;12(9):2756.PubMedPubMedCentralCrossRef
87.
Matsumoto A, Kanaoka Y, Baba T, et al. Result of thoracic endovascular aortic repair for patients with esophageal cancer. World J Surg. 2018;42(5):1551–8.PubMedCrossRef
88.
Watanabe M, Nakajima M, Nishikawa K, et al. Thoracic endovascular aortic repair for esophageal cancer invading the thoracic aorta: a questionnaire survey study. Esophagus. 2020;17(1):74–80.PubMedCrossRef
89.
Nakajima M, Muroi H, Kikuchi M, et al. Salvage esophagectomy combined with partial aortic wall resection following thoracic endovascular aortic repair. Gen Thorac Cardiovasc Surg. 2018;66(12):736–43.PubMedCrossRef
90.
Yamatsuji T, Naomoto Y, Shirakawa Y, et al. Intra-aortic stent graft in oesophageal carcinoma invading the aorta. Prophylaxis for fatal haemorrhage. Int J Clin Pract. 2006;60(12):1600–3.PubMedCrossRef
91.
Makino T, Yasuda T, Shiraishi O, et al. Aortic stent-grafting facilitates a successful resection after neoadjuvant treatment of a cT4 esophageal cancer. J Thorac Cardiovasc Surg. 2014;148(5):e211–2.PubMedCrossRef
92.
Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140(3):1084–91.PubMedCrossRef
93.
Evans JA, Early DS, Fukami N, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76(6):1087–94.PubMedCrossRef
94.
Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7–42.PubMedCrossRef
95.
Whiteman DC, Appleyard M, Bahin FF, et al. Australian clinical practice guidelines for the diagnosis and management of Barrett’s esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol. 2015;30(5):804–20.PubMedCrossRef
96.
Shaheen NJ, Falk GW, Iyer PG, et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30–50 (quiz 1).PubMedCrossRef
97.
Fock KM, Talley N, Goh KL, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus. Gut. 2016;65(9):1402–15.PubMedCrossRef
98.
Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy. 2017;49(2):191–8.PubMedCrossRef
99.
Qumseya B, Sultan S, Bain P, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc. 2019;90(3):335–59 (e2).PubMedCrossRef
Metadata
Title
Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2
Authors
Yuko Kitagawa
Ryu Ishihara
Hitoshi Ishikawa
Yoshinori Ito
Takashi Oyama
Tsuneo Oyama
Ken Kato
Hiroyuki Kato
Hirofumi Kawakubo
Hiroshi Kawachi
Shiko Kuribayashi
Koji Kono
Takashi Kojima
Hiroya Takeuchi
Takahiro Tsushima
Yasushi Toh
Kenji Nemoto
Eisuke Booka
Tomoki Makino
Satoru Matsuda
Hisahiro Matsubara
Masayuki Mano
Keiko Minashi
Tatsuya Miyazaki
Manabu Muto
Taiki Yamaji
Tomoki Yamatsuji
Masahiro Yoshida
Publication date
30-03-2023
Publisher
Springer Nature Singapore
Published in
Esophagus / Issue 3/2023
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-023-00994-1

Other articles of this Issue 3/2023

Esophagus 3/2023 Go to the issue

Original Article

Prognostic impact of endoscopic response evaluation after neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a nationwide validation study

Original Article

Differential prognostic significance of sarcopenia in metastatic esophageal squamous and adenocarcinoma

Original Article

The long-term efficacy of transoral incisionless fundoplication with Medigus Ultrasonic Surgical Endostapler (MUSE) for gastroesophageal reflux disease

Original Article

Predictors of the difficulty of transcervical subcarinal lymph node dissection for esophageal cancer

Original Article

Endoscopic findings suggestive of a high risk of non-radical cure after definitive chemoradiotherapy for cT1bN0M0 esophageal squamous cell carcinoma

Original Article

Significance of dissection in each regional lymph-node station of esophageal cancer based on efficacy index and recurrence patterns after curative esophagectomy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits